Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Catalyst Pharmaceuticals (CPRX) Treasury Shares (2016 - 2026)

Catalyst Pharmaceuticals filings provide 10 years of Treasury Shares readings, the most recent being $615765.0 for Q1 2026.

  • On a quarterly basis, Treasury Shares changed N/A to $615765.0 in Q1 2026 year-over-year; TTM through Mar 2026 was $615765.0, a N/A change, with the full-year FY2025 number at $752626.0, up 6.16% from a year prior.
  • Treasury Shares hit $615765.0 in Q1 2026 for Catalyst Pharmaceuticals, down from $752626.0 in the prior quarter.
  • In the past five years, Treasury Shares ranged from a high of $1.0 million in Q4 2022 to a low of -$1.0 million in Q3 2022.
  • Median Treasury Shares over the past 4 years was $615765.0 (2026), compared with a mean of $153907.3.
  • The widest YoY moves for Treasury Shares: up 145.28% in 2022, down 697.01% in 2022.
  • Catalyst Pharmaceuticals' Treasury Shares stood at $1.0 million in 2022, then fell by 29.1% to $708960.0 in 2024, then increased by 6.16% to $752626.0 in 2025, then dropped by 18.18% to $615765.0 in 2026.
  • The last three reported values for Treasury Shares were $615765.0 (Q1 2026), $752626.0 (Q4 2025), and $708960.0 (Q4 2024) per Business Quant data.